US Pre-Market SEC Filings Roundup — September 14, 2026
Overnight filings reveal a market bifurcated between aggressive capital markets activity and fundamental business stress. The SPAC space shows renewed IPO energy with two new blank-check filings (Eaglesky Acquisition Corp, Leader's Advantage) targeting $250M combined, while Embrace Change Acquisition Corp. faces a failed merger, highlighting the binary outcomes in this sector. Corporate governance is in flux, with leadership changes at VinFast, ZK International, and Woodside Energy, while insider confidence signals are mixed: a bullish CEO purchase at NEONC TECHNOLOGIES contrasts with Larry Ellison's cancelled Oracle sale plan. Financial health indicators are divergent: UNFI posted a strong operational turnaround with a $202M swing to net income, while InPoint Commercial Real Estate cut its distribution and Faraday Future flagged ongoing going-concern risks. The IPO pipeline is active with Electra Therapeutics ($296.6M expected proceeds), Einride AB (EV/autonomous trucking), and Radiopharm Theranostics filing shelf registrations. Sector-wise, healthcare/biotech dominates with multiple clinical trial updates (Clearmind Medicine, Lipocine) and a significant insider stake disclosure (Dr. Phillip Frost in Safe Pro Group). Capital allocation trends show Prudential executing a consistent buyback program while Nomura has paused its repurchases after hitting its monetary cap. The overall tone is cautiously constructive, with capital formation accelerating but underlying operational challenges persisting across several sectors.